Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
Open Access
- 17 April 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 10 (2) , 1-11
- https://doi.org/10.1186/bcr1994
Abstract
Introduction: Vitamin D receptor (VDR) genotypes may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D, but epidemiological studies have been inconsistent. Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans, has rarely been examined. Methods: We assessed the effects of two frequently analyzed polymorphisms (FokI and TaqI) and two potentially functional variants (VDR-5132 and Cdx2) in the VDR gene, which thus far have not been analyzed with respect to breast cancer risk, on postmenopausal breast cancer risk in a population-based, case-control study including 1,408 patients (cases) and 2,612 control individuals (controls) matched for year of birth. Odds ratios (ORs) for breast cancer adjusted for potential confounders were calculated for genotypes and estimated haplotypes. Results: No differences in serum 25(OD)D concentrations by VDR genotype were observed. None of the analyzed polymorphisms was associated with overall risk for postmenopausal breast cancer. However, the TaqI polymorphism was associated with a significantly increased risk for oestrogen receptor positive tumours (OR = 1.18, 95% confidence interval [CI] = 1.00 to 1.38, comparing t allele carriers with noncarriers) but not for oestrogen receptor negative tumours (OR = 0.88, 95% CI = 0.69 to 1.13; P for interaction = 0.04). Haplotype analysis revealed the haplotype FtCA (FokI F, TaqI t, VDR-5132 C, Cdx2 A), which contains the TaqI t allele, to be associated with a significantly greater breast cancer risk as compared with the most frequent haplotype FTCG (OR = 1.43, 95% CI = 1.00 to 2.05). No significant interaction between VDR genotypes or haplotypes and 25(OH)D was observed. Conclusion: Our results support potential effects of VDR polymorphisms on postmenopausal breast cancer risk and possible differential effects of receptor status of the tumour. However, further studies focusing on the influence of polymorphisms and haplotypes on VDR functionality, activity and concentration are needed.Keywords
This publication has 46 references indexed in Scilit:
- Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer riskThe Prostate, 2007
- Vitamin D and cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Vitamin D Receptor Gene Polymorphisms and Breast Cancer RiskClinical Cancer Research, 2004
- Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer riskPharmacogenetics, 2004
- Vitamin D receptor gene polymorphisms in breast cancerExperimental & Molecular Medicine, 2003
- Cdx-2 Polymorphism in the Promoter Region of the Human Vitamin D Receptor Gene Determines Susceptibility to Fracture in the ElderlyJournal of Bone and Mineral Research, 2003
- Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesisFrontiers in Bioscience-Landmark, 2001
- No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancerCarcinogenesis: Integrative Cancer Research, 1999
- The Caudal-Related Homeodomain Protein Cdx-2 Regulates Vitamin D Receptor Gene Expression in the Small IntestineJournal of Bone and Mineral Research, 1999
- The Effects of Chemotherapy Including Cisplatin on Vitamin D Metabolism.Endocrine Journal, 1993